Sort
78,016 grants matching “breast cancer”
Intra-operative confocal imaging to guide Mohs surgery
$785,309Milind Rajadhyaksha · Sloan-Kettering Inst Can Research · R01 · FY2011 · EB
AXL-TARGETING ANTIBODY-DRUG CONJUGATE AS NOVEL THERAPY FOR TRIPLE NEGATIVE BREAST CANCER
$785,302Mayo Clinic · · FY2019 · Defense Health Agency
Development of a 3D Imaging Diagnostic Tool for the Improved Characterization of Metastatic Melanoma
$785,292Thomas Steven Villani · Visikol, Inc. · R44 · FY2022 · CA
PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND ENDPOINT BIOMARKERS. TASK ORDER TITLE: URINARY BLADDER CANCER PREVENTIO
$785,160Chinthalapally V. Rao · University Of Oklahoma Hlth Sciences Ctr · N01 · FY2020 · CA
Epidemiology of Putative Causal Variants in the Multiethnic Cohort
$785,130Loic Le Marchand · University Of Hawaii At Manoa · U01 · FY2012 · HG
Molecular Analysis of Breast Cancer Metastasis to the Brain
$785,037Patricia Schriver Steeg · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Molecular Biology of the Metastatic Phenotype
$785,037Patricia Schriver Steeg · Division Of Clinical Sciences - Nci · ZIA · FY2015 · CA
Cancer Center Support Grant
$785,000Richard A. Van Etten · University Of California-Irvine · P30 · FY2020 · CA
NAVAJO NATION BREAST & CERVICAL CANCER PREVENTION PROGRAM
$785,000Sally Ann Joe · Navajo Nation Division Of Health · U58 · FY2007 · DP
COMBINED DIGITAL X-RAY AND ULTRASOUND BREAST IMAGING
$784,978Paul L Carson · University Of Michigan At Ann Arbor · R01 · FY2006 · CA
Carolina Breast Cancer Study
$784,939Robert C Millikan · Univ Of North Carolina Chapel Hill · P50 · FY2013 · CA
Assessment of ultrasound-facilitated neurotherapeutics in Alzheimer's disease
$784,859Elisa E Konofagou · Columbia University Health Sciences · R56 · FY2024 · AG
TURNING BREAST CANCER CELLS AGAINST THEMSELVES AS THE NEXT-GENERATION IMMUNOTHERAPY
$784,602Dana-Farber Cancer Institute, Inc. · · FY2025 · Defense Health Agency
ESTROGEN RECEPTOR BETA P53 SIGNALING AXIS A NEW THERAPEUTIC TARGET IN TRIPLE-NEGATIVE BREAST CANCER
$784,575Baylor College Of Medicine · · FY2019 · Defense Health Agency
CDK11B: A DRUGGABLE VULNERABILITY IN BREAST CANCER
$784,555Yale Univ · · FY2020 · Defense Health Agency
TRAIL-induced Cell Death in Breast Cancer Cells
$784,437Stanley Lipkowitz · Division Of Clinical Sciences - Nci · ZIA · FY2016 · CA
Impact of Cellular and Extracellular Host Components on Tumor Progression
$784,417Richard O Hynes · Massachusetts Institute Of Technology · U54 · FY2011 · CA
Subclonal heterogeneity and outcome disparities in Triple-Negative Breast Cancer among African Americans
$784,127Leif W Ellisen · Massachusetts General Hospital · R01 · FY2025 · CA
The Worcester Venous Thromboembolism Study
$784,114Frederick A Spencer · Univ Of Massachusetts Med Sch Worcester · R01 · FY2010 · HL
HYBRID, FLAT-PANEL, ACTIVE MATRIX MAMMOGRAPHIC IMAGER
$784,077University Of Michigan At Ann Arbor · R01 · FY2000 · CA
Development of TGF-beta antagonists for cancer therapy
$784,065Lalage Wakefield · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
The Role of Carboxypeptidase E in Cancer
$783,912Yoke P Loh · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2011 · HD
Preclinical Testing of Drug Combinations (HDAC, mTOR, CDK and MYC Inhibitors)
$783,832Beverly Mock · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
INDUCING BRCANESS TO SYNERGIZE WITH PARP INHIBITORS IN BREAST CANCER
$783,822Baylor College Of Medicine · · FY2019 · Defense Health Agency
BRCA1 AND BRCA2 IN AFRICAN-AMERICAN AND LATINO FAMILIES
$783,169University Of Southern California · R01 · FY2002 · CA